Developer docs
API playgroundTry for free, no card

Search company profiles

Be Biopharma

Full company profile

uuid00009vm

Namestring
Be Biopharma
Legal namestring
Be Biopharma, Inc.
Websiteurl
be.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Be Biopharma is a clinical-stage biotechnology company founded in October 2020 by David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children's Research Institute. The company is headquartered in Cambridge, Massachusetts, and operates as a privately held Delaware corporation with no parent company. As of 2025 it employs between 51 and 100 people and has raised over $356 million in cumulative investor commitments across a $52 million Series A (2020), a $130 million Series B (2022), an $82 million financing (2024), and a $92 million Series C (2025), backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Bristol Myers Squibb, Takeda Ventures, Alta Partners, Longwood Fund, Seattle Children's Research Institute, Pathway to Cures, and Nextech.

The company's product platform is Engineered B Cell Medicines (BCMs), which use CRISPR/Cas9 and AAV-mediated homology directed repair to insert therapeutic genes into primary human B cells. These engineered B cells are expanded ex vivo and differentiated into plasma cells that engraft in bone marrow without preconditioning and secrete therapeutic proteins at constant levels. The company's lead program, BE-101, is in a Phase 1/2 trial (BeCoMe-9) for hemophilia B and has received FDA Orphan Drug and Fast Track designations. A second program, BE-102, was developed using AI-guided protein design and is being advanced toward IND for hypophosphatasia. The company is also pursuing oncology applications of the BCM platform, including sustained delivery of bispecific T cell engagers. Manufacturing is supported by a strategic collaboration with Resilience.

Be Biopharma is pre-revenue and does not currently generate product sales. Its future revenue model is expected to rely on commercialization of BCM therapeutics upon regulatory approval, supported by clinical development partnerships and ongoing interactions with the FDA. Distribution is currently limited to clinical trial sites, with the BeCoMe-9 trial planning to enroll up to 24 participants across two parts monitored for approximately 52 weeks. The company's customer segments are patient populations with serious genetic diseases: hemophilia B patients (approximately 40,000 globally), hypophosphatasia patients (approximately 50,000 in the US and over 100,000 worldwide), and oncology patients who could benefit from sustained delivery of antitumor biologics.

Short descriptiontext

Be Biopharma is a clinical-stage biotechnology company developing Engineered B Cell Medicines (BCMs), using CRISPR/Cas9 and AAV-mediated HDR to engineer B cells that durably secrete therapeutic proteins for patients with hemophilia B, hypophosphatasia, and cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered B cell therapies, cell therapy platform, biopharmaceutical drug development, protein replacement therapy, rare disease therapeutics
Industry3 codes
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage company, Be Bio does not yet generate revenue. The company is developing Engineered B Cell Medicines (BCMs) for genetic diseases (hemophilia B, hypophosphatasia) and cancer. Future revenue is expected from commercialization of BCM therapeutics upon regulatory approval.

be.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Be Biopharma develops Engineered B Cell Medicines (BCMs), a new class of cellular medicines in which primary human B cells are precision-engineered ex vivo using CRISPR/Cas9 and AAV-mediated homology directed repair to secrete therapeutic proteins continuously after engraftment as plasma cells in the bone marrow. The company's lead product candidate BE-101 is in Phase 1/2 clinical trials (BeCoMe-9) for hemophilia B, expressing human Factor IX; BE-102 is a preclinical development candidate for hypophosphatasia expressing tissue-nonspecific alkaline phosphatase.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BE-101 demonstrated stable FIX production for >168 days in preclinical studies
+4 more records
Product overview1 text field

Be Biopharma is pioneering Engineered B Cell Medicines (BCMs), a new class of cellular medicines built on a programmable platform. The core BCM platform enables precise genome editing of a patient's own B cells to produce therapeutic proteins continuously. The company has two named product candidates: BE-101 (for hemophilia B, in Phase 1/2 clinical trials) and BE-102 (for hypophosphatasia, in preclinical development). Both programs leverage the BCM platform's ability to create durable, titratable, and re-dosable therapeutics without preconditioning.

Product and service2 records
1BE-101
CategoryEngineered B Cell Medicine — Hemophilia B Program
Description

BE-101 is a first-in-class Engineered B Cell Medicine (BCM) engineered using CRISPR/Cas9 and AAV-mediated HDR to insert the human Factor IX (FIX) gene into primary human B cells for the treatment of hemophilia B. BE-101 is designed to deliver continuous expression of active FIX with a single infusion, with potential to be titratable and re-dosable, without the need for preconditioning or immunosuppression.

2BE-102
CategoryEngineered B Cell Medicine — Hypophosphatasia Program
Description

BE-102 is a first-in-class Engineered B Cell Medicine engineered using AI-guided protein design to modify primary human B cells to produce tissue-nonspecific alkaline phosphatase (TNSALP/ALP) for the potential treatment of hypophosphatasia. BE-102 is designed to provide continuous secretion of therapeutic ALP from a single infusion without the need for preconditioning.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-05-19
Description

Strategic collaboration announced May 19, 2022 to manufacture engineered B cells, a new class of cellular medicines. Resilience provides manufacturing capabilities for Be Bio's BCM platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology origin - Be Bio was founded by B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children's Research Institute. The institute is an investor and research collaborator. Joint research conducted on bispecific T cell engagers for leukemia treatment.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaborative research and development agreement with NHLBI, part of the National Institutes of Health, to study engraftment of ex-vivo-generated plasma cells in non-human primates. Study published in Molecular Therapy journal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company whose lead asset etranacogene dezaparvovec (Hemgenix) is the first approved gene therapy for hemophilia B. Competes head-to-head with BE-101 in hemophilia B but uses a one-time AAV approach rather than re-dosable engineered B cells.

TypeDirect peer
Description

Leading CRISPR/Cas9-based gene editing company developing CTX001 (Casgevy) for sickle cell disease and beta-thalassemia. Uses similar gene editing modality as Be Bio's BCM platform and targets similar patient populations with durable genetic disease cures.

TypeBroad incumbent
Description

Markets BeneFIX (recombinant Factor IX) and acquired Global Blood Therapeutics. A major incumbent in hemophilia B treatment and a likely strategic acquirer/partner for cell therapy developers seeking commercial infrastructure.

TypeBroad incumbent
Description

Developer of Roctavian, the first approved AAV gene therapy for hemophilia A, with active programs in hypophosphatasia (Voxzogo) and rare diseases directly overlapping Be Bio's BE-101 and BE-102 target indications.

TypeBroad incumbent
Description

Global leader in plasma-derived and recombinant coagulation therapies (Idelvion, Afstyla for hemophilia B; asfotase alfa/Strensiq for hypophosphatasia). Directly competes in both of Be Bio's lead indications with established patient and provider relationships.

TypeDirect peer
Description

Clinical-stage gene editing company developing zinc finger nuclease-based therapies, including programs for hemophilia A and B. Uses genome editing to produce therapeutic proteins from patient cells, conceptually similar to Be Bio's B cell engineering approach.

TypeEmerging player
Description

Emerging gene therapy company developing AAV-based treatments for rare diseases including hemophilia. Competes with Be Bio in the protein-replacement space but via one-time gene therapy rather than re-dosable cellular medicine.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing non-viral lipid nanoparticle-based gene therapies for hemophilia and other rare diseases. Represents an alternative redosable gene therapy approach competing with Be Bio's redosability advantage.

9Sigilon Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company developing engineered cell encapsulated therapies for rare diseases including hemophilia A and lysosomal storage disorders. Competes with Be Bio on protein replacement from engineered cells without preconditioning.

TypeEmerging player
Description

Emerging engineered cell therapy company focused on in vivo cell engineering using mRNA-LNP delivery. Operates in adjacent cell engineering space targeting similar protein-replacement and autoimmune indications as Be Bio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Be Biopharma

Cell Therapy / Biopharmaceuticalsbe.bio

Be Biopharma is a clinical-stage biotechnology company developing Engineered B Cell Medicines (BCMs), using CRISPR/Cas9 and AAV-mediated HDR to engineer B cells that durably secrete therapeutic proteins for patients with hemophilia B, hypophosphatasia, and cancer.

What Be Biopharma does

Be Biopharma is a clinical-stage biotechnology company founded in October 2020 by David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children's Research Institute. The company is headquartered in Cambridge, Massachusetts, and operates as a privately held Delaware corporation with no parent company. As of 2025 it employs between 51 and 100 people and has raised over $356 million in cumulative investor commitments across a $52 million Series A (2020), a $130 million Series B (2022), an $82 million financing (2024), and a $92 million Series C (2025), backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Bristol Myers Squibb, Takeda Ventures, Alta Partners, Longwood Fund, Seattle Children's Research Institute, Pathway to Cures, and Nextech.

The company's product platform is Engineered B Cell Medicines (BCMs), which use CRISPR/Cas9 and AAV-mediated homology directed repair to insert therapeutic genes into primary human B cells. These engineered B cells are expanded ex vivo and differentiated into plasma cells that engraft in bone marrow without preconditioning and secrete therapeutic proteins at constant levels. The company's lead program, BE-101, is in a Phase 1/2 trial (BeCoMe-9) for hemophilia B and has received FDA Orphan Drug and Fast Track designations. A second program, BE-102, was developed using AI-guided protein design and is being advanced toward IND for hypophosphatasia. The company is also pursuing oncology applications of the BCM platform, including sustained delivery of bispecific T cell engagers. Manufacturing is supported by a strategic collaboration with Resilience.

Be Biopharma is pre-revenue and does not currently generate product sales. Its future revenue model is expected to rely on commercialization of BCM therapeutics upon regulatory approval, supported by clinical development partnerships and ongoing interactions with the FDA. Distribution is currently limited to clinical trial sites, with the BeCoMe-9 trial planning to enroll up to 24 participants across two parts monitored for approximately 52 weeks. The company's customer segments are patient populations with serious genetic diseases: hemophilia B patients (approximately 40,000 globally), hypophosphatasia patients (approximately 50,000 in the US and over 100,000 worldwide), and oncology patients who could benefit from sustained delivery of antitumor biologics.

Be Biopharma firmographics

Firmographics
Name
Be Biopharma
Legal name
Be Biopharma, Inc.
Website
https://be.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Be Biopharma is a clinical-stage biotechnology company developing Engineered B Cell Medicines (BCMs), using CRISPR/Cas9 and AAV-mediated HDR to engineer B cells that durably secrete therapeutic proteins for patients with hemophilia B, hypophosphatasia, and cancer.
Ownership category
akta.pro rank

Be Biopharma industry classification

Industry
Product category
Cell Therapy / Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)

Keywords

  • Engineered B cell therapies
  • Cell therapy platform
  • Biopharmaceutical drug development
  • Protein replacement therapy
  • Rare disease therapeutics

Where Be Biopharma is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Be Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Revenue: As a clinical-stage company, Be Bio does not yet generate revenue. The company is developing Engineered B Cell Medicines (BCMs) for genetic diseases (hemophilia B, hypophosphatasia) and cancer. Future revenue is expected from commercialization of BCM therapeutics upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Be Biopharma product offering

Product offering

Core offering

Be Biopharma develops Engineered B Cell Medicines (BCMs), a new class of cellular medicines in which primary human B cells are precision-engineered ex vivo using CRISPR/Cas9 and AAV-mediated homology directed repair to secrete therapeutic proteins continuously after engraftment as plasma cells in the bone marrow. The company's lead product candidate BE-101 is in Phase 1/2 clinical trials (BeCoMe-9) for hemophilia B, expressing human Factor IX; BE-102 is a preclinical development candidate for hypophosphatasia expressing tissue-nonspecific alkaline phosphatase.

Product overview

Be Biopharma is pioneering Engineered B Cell Medicines (BCMs), a new class of cellular medicines built on a programmable platform. The core BCM platform enables precise genome editing of a patient's own B cells to produce therapeutic proteins continuously. The company has two named product candidates: BE-101 (for hemophilia B, in Phase 1/2 clinical trials) and BE-102 (for hypophosphatasia, in preclinical development). Both programs leverage the BCM platform's ability to create durable, titratable, and re-dosable therapeutics without preconditioning.

Differentiator

Problem solved

Functional benefit

Products and services

  • BE-101 BE-101 is a first-in-class Engineered B Cell Medicine (BCM) engineered using CRISPR/Cas9 and AAV-mediated HDR to insert the human Factor IX (FIX) gene into primary human B cells for the treatment of hemophilia B. BE-101 is designed to deliver continuous expression of active FIX with a single infusion, with potential to be titratable and re-dosable, without the need for preconditioning or immunosuppression.
  • BE-102 BE-102 is a first-in-class Engineered B Cell Medicine engineered using AI-guided protein design to modify primary human B cells to produce tissue-nonspecific alkaline phosphatase (TNSALP/ALP) for the potential treatment of hypophosphatasia. BE-102 is designed to provide continuous secretion of therapeutic ALP from a single infusion without the need for preconditioning.

Quantifiable outcome

  • BE-101 demonstrated stable FIX production for >168 days in preclinical studies
  • +4 more outcomes

Companies that use Be Biopharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Be Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Be Biopharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic and core.

  • ResiliencestrategicStrategic or Co-development Partner · 19 May 2022Strategic collaboration announced May 19, 2022 to manufacture engineered B cells, a new class of cellular medicines. Resilience provides manufacturing capabilities for Be Bio's BCM platform.
  • Seattle Children's Research InstitutecoreStrategic or Co-development PartnerTechnology origin - Be Bio was founded by B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children's Research Institute. The institute is an investor and research collaborator. Joint research conducted on bispecific T cell engagers for leukemia treatment.
  • National Heart, Lung, and Blood Institute (NHLBI)strategicStrategic or Co-development PartnerCollaborative research and development agreement with NHLBI, part of the National Institutes of Health, to study engraftment of ex-vivo-generated plasma cells in non-human primates. Study published in Molecular Therapy journal.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Be Biopharma competitors and assessment

Company assessment

Direct peers

  • uniQure: Clinical-stage gene therapy company whose lead asset etranacogene dezaparvovec (Hemgenix) is the first approved gene therapy for hemophilia B. Competes head-to-head with BE-101 in hemophilia B but uses a one-time AAV approach rather than re-dosable engineered B cells.
  • CRISPR Therapeutics: Leading CRISPR/Cas9-based gene editing company developing CTX001 (Casgevy) for sickle cell disease and beta-thalassemia. Uses similar gene editing modality as Be Bio's BCM platform and targets similar patient populations with durable genetic disease cures.
  • Sangamo Therapeutics: Clinical-stage gene editing company developing zinc finger nuclease-based therapies, including programs for hemophilia A and B. Uses genome editing to produce therapeutic proteins from patient cells, conceptually similar to Be Bio's B cell engineering approach.

Broad incumbents

  • Pfizer (Hemophilia Franchise): Markets BeneFIX (recombinant Factor IX) and acquired Global Blood Therapeutics. A major incumbent in hemophilia B treatment and a likely strategic acquirer/partner for cell therapy developers seeking commercial infrastructure.
  • BioMarin Pharmaceutical: Developer of Roctavian, the first approved AAV gene therapy for hemophilia A, with active programs in hypophosphatasia (Voxzogo) and rare diseases directly overlapping Be Bio's BE-101 and BE-102 target indications.
  • CSL Behring: Global leader in plasma-derived and recombinant coagulation therapies (Idelvion, Afstyla for hemophilia B; asfotase alfa/Strensiq for hypophosphatasia). Directly competes in both of Be Bio's lead indications with established patient and provider relationships.

Emerging players

  • StrideBio: Emerging gene therapy company developing AAV-based treatments for rare diseases including hemophilia. Competes with Be Bio in the protein-replacement space but via one-time gene therapy rather than re-dosable cellular medicine.
  • Generation Bio: Clinical-stage genetic medicines company developing non-viral lipid nanoparticle-based gene therapies for hemophilia and other rare diseases. Represents an alternative redosable gene therapy approach competing with Be Bio's redosability advantage.
  • Sigilon Therapeutics: Clinical-stage cell therapy company developing engineered cell encapsulated therapies for rare diseases including hemophilia A and lysosomal storage disorders. Competes with Be Bio on protein replacement from engineered cells without preconditioning.
  • Capstan Therapeutics: Emerging engineered cell therapy company focused on in vivo cell engineering using mRNA-LNP delivery. Operates in adjacent cell engineering space targeting similar protein-replacement and autoimmune indications as Be Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Be Biopharma social profiles

Digital presence

Be Biopharma compliance and trust

Trust signal

Compliance2 records

Be Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Be Biopharma leadership team

Management profile

Number of profiles

Profiles9 records

Be Biopharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Be Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Be Biopharma

What does Be Biopharma do?

Be Biopharma develops Engineered B Cell Medicines (BCMs), a new class of cellular medicines in which primary human B cells are precision-engineered ex vivo using CRISPR/Cas9 and AAV-mediated homology directed repair to secrete therapeutic proteins continuously after engraftment as plasma cells in the bone marrow. The company's lead product candidate BE-101 is in Phase 1/2 clinical trials (BeCoMe-9) for hemophilia B, expressing human Factor IX; BE-102 is a preclinical development candidate for hypophosphatasia expressing tissue-nonspecific alkaline phosphatase.

Is Be Biopharma a public or private company?

Be Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Be Biopharma founded?

Be Biopharma was founded in 2020. It employs 11 to 50 people.

Where is Be Biopharma based?

Be Biopharma is headquartered in Cambridge, United States, in the North America region.

How does Be Biopharma make money?

One revenue line is on record: biopharmaceutical Product Revenue.

Who are Be Biopharma's main competitors?

Direct peers on record are uniQure, CRISPR Therapeutics and Sangamo Therapeutics. Broad incumbents are Pfizer (Hemophilia Franchise), BioMarin Pharmaceutical and CSL Behring. Emerging players are StrideBio, Generation Bio, Sigilon Therapeutics and Capstan Therapeutics.

Does Be Biopharma have an API?

No public API is recorded for Be Biopharma.

What industry is Be Biopharma in?

Be Biopharma's product category is Cell Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SeattlechildrensChildren’s Researchers Share Progress at American Society of GeneSeattle Children’s Research Institute showcased pivotal research advancements in gene and cell therapies at the American Society of Gene and Cell Therapy Annual Meeting in Los Angeles. The institute's labs are collaborating with biotechnology startups GentiBio and Be Biopharma to advance engineered cell therapies for conditions including cancer, Type 1 diabetes, and hemophilia toward human clinical trials.BioSpaceBe Bio bins hemophilia B cell therapy trial—the biotech’s lead programBe Biopharma has terminated its Phase 1/2 BeCoMe-9 clinical trial for B cell therapy BE-101 in hemophilia B, citing a strategic business decision unrelated to safety concerns; the trial had enrolled only five of 24 expected patients before being discontinued. The termination marks another setback in the hemophilia treatment space, following Pfizer's decision to end its gene therapy Beqvez and BioMarin's removal of hemophilia A therapy Roctavian from its portfolio due to slow uptake. BE-101 had no other listed trials, leaving Be Bio with only a preclinical asset called BE-102 for hypophosphatasia.GlobeNewswireHemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightDelveInsight released a hemophilia pipeline report covering 55+ drugs from 50+ companies, including Novo Nordisk, Roche, and Regeneron. Recent updates include Metagenomi's MGX-001 preclinical data and Novo Nordisk's FDA BLA for Denecimig. The report also highlights clinical trial data for NXT007 and other therapies.FundraiseinsiderList of Funded Biotech Startups (2025)The article presents a curated list of biotech startups that have secured recent funding, highlighting their focus areas such as gene therapy, AI-driven manufacturing, and diagnostics. It provides specific examples like Be Biopharma and Formation Bio, detailing their funding stages and strategic goals for advancing clinical development.ResilienceBiologics Development CDMOResilience, a biologics development CDMO, outlines its strategic partnerships and collaborations aimed at advancing cell and gene therapies. Key initiatives include manufacturing investigational treatments for BridgeBio, developing rare disease programs with Be Bio, and establishing a joint venture with MD Anderson Cancer Center known as CTMC. The company also maintains R&D alliances with Harvard and provides GMP biomanufacturing services for projects supported by the California Institute of Regenerative Medicine.Pulse 2.0Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell MedicinesBe Bio raised $82 million to advance its engineered B cell medicines, with BE-101 for Hemophilia B entering Phase 1/2 and BE-102 nominated for Hypophosphatasia. The funding will support clinical proof of concept for BE-101 and development of BE-102.BioSpaceBe Bio Announces $82 Million Financing and Transition to Clinical Stage CompanyBe Bio announced $82 million in financing to advance BE-101 for Hemophilia B and BE-102 for Hypophosphatasia. BE-101's Phase 1/2 trial is open for enrollment, and BE-102 was nominated as a development candidate. The company is transitioning to a clinical-stage company with new senior leadership.FinSMEsBe Biopharma Raises $82M in FinancingBe Biopharma raised $82 million in a financing round backed by investors including ARCH Venture Partners, Bristol Myers Squibb, and Takeda Ventures. The company plans to utilize these funds to achieve clinical proof of concept for its lead candidate BE-101 and advance the development of BE-102. This funding supports ongoing efforts following the US FDA's clearance of the BE-101 Investigational New Drug application and grant of Fast Track designation.MarketScreenerBe Bio Announces $82 Million Financing RoundBe Bio raised $82 million in a financing round, with participation from Bristol Myers Squibb and Takeda Ventures. The company also hired Suha Patel and Kiran Patki as senior vice presidents. Proceeds will fund clinical proof of concept for BE-101 and development of BE-102 for Hypophosphatasia.VC News DailyBe Bio Scores $82MBe Biopharma, a Cambridge-based biotech company pioneering Engineered B Cell Medicines, announced an $82 million financing round backed by major venture capital firms and pharmaceutical companies including Bristol Myers Squibb and Takeda Ventures. The funding will support clinical proof of concept for its lead program BE-101 for Hemophilia B and advance its second development candidate BE-102 for Hypophosphatasia. Be Bio was founded in October 2020 and focuses on developing cell therapies for genetic diseases, cancer, and other serious conditions.